Uncovering untreated heart disease with AI and big data: A conversation with egnite’s Joel Portice and Edwards Lifesciences’ Don Bobo

The Venture

Cardiovascular disease remains the number one killer in every developed country, but only one in ten US patients with severe heart ailments received treatment in 2022. Egnite, a healthcare start-up, has ambitious plans to dramatically improve treatment of heart disease by harnessing the power of AI and big data to identify patients who fell through the cracks after being diagnosed. Egnite was spun out from Edwards Lifesciences, a California-based medical technology company, in early 2021. Egnite’s digital platform, CardioCare, steadily gained acceptance among clinicians, physicians, and hospitals, as the industry rapidly adopted new technology during the pandemic. Don Bobo, corporate vice president at Edwards, and Joel Portice, president and CEO of egnite, sat down with McKinsey’s Andrew Roth to discuss the CardioCare platform, the relationship between egnite and Edwards, and the lifesaving capabilities of AI and big data.

---

Comments and opinions expressed by interviewees are their own and do not represent or reflect the opinions, policies, or positions of McKinsey & Company or have its endorsement.

See www.mckinsey.com/privacy-policy for privacy information